CLARITY IBD: Anti-SARS-CoV-2 antibody and vaccination responses in patients treated with infliximab

Dr Philip Smith, Digital and Education Editor of Gut and Consultant Gastroenterologist at the Royal Liverpool Hospital, interviews Dr Tariq Ahmad and Dr Nick Kennedy, both from the Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, UK. This special Gut podcast is focused on ‘Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab’ which is published in paper copy in Gut in May 2021 and the recently published paper ‘Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines’. Acknowledgements: The CLARITY IBD team would like to thank the CLARITY IBD team in Exeter, all of the 92 CLARITY IBD sites and over 7000 participants in the study. We are grateful to support from the NIHR CRN, Crohn's & Colitis UK and our funders. The related links: https://gut.bmj.com/content/early/2021/04/25/gutjnl-2021-324789

https://gut.bmj.com/content/70/5/865